National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 1 of 41
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
NCT07683104
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
NCT07015996
BPL-1357 Against H1N1 Influenza Virus Challenge
NCT07215858
Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
NCT07040319
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
NCT06918990
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
NCT07536308
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
NCT06705478
Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation
NCT07549503
Dasatinib for HIV-1 Reservoir Reduction
NCT07342491
LYmph Node eXamination in Cat Allergen Immunotherapy
NCT07447869
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT07262983
THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins
NCT07271381
Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers
NCT05652478
The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States
NCT07027826
Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without Thymectomy
NCT07416201
Modeling Host-Pathogen Interaction Using Lymphoid Organoids
NCT06479837
Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV
NCT07390474
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
NCT07390955
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
NCT07103746
EVR and EPO for Liver Transplant Tolerance
NCT06832189
Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy
NCT06819176
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
NCT06517693
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
NCT07108387
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
NCT07221162
Improving Physical Ability and Cellular Senescence Elimination in HIV
NCT07144293
Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
NCT07202598
Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)
NCT06919003
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
NCT07169318
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
NCT06665646
pH1N1 Blinded Challenge Study
NCT07110532
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
NCT06974877
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
NCT07111078
Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study
NCT06959771
Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori
NCT06871579
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
NCT06908096
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
NCT06863142
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
NCT06504160
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
NCT06796686
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
NCT06476132
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
NCT06730126
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
NCT06812494
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
NCT06118515
Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)
NCT06709521
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
NCT06477653
Belatacept in Heart Transplantation
NCT06478017
A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
NCT06732414
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
NCT06607003
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
NCT05600920
Cardamom and Topical Roseomonas in Atopic Dermatitis
NCT06096857
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
NCT05947071
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets.Report a data error.